Israel Active

(Thanks to Israel21c) Here is a new report about the TTFields scalp device from Israel’s Novocure that slows the growth of brain tumors.  (Previously reported in Nov 2014).

(Thanks to Israel21c) Two Israeli startups have received Israeli Government grants to develop their products for diagnosing pneumonia.  RespiDX’s Respimometer has sensors to measure breathing.  NanoVation-GS’s stick-on patch has a film with a nano-sensor to measure respiration.

Israeli biotech SteadyMed has developed a disposable patch pump delivery system to administer medicines safely and accurately into the body.  SteadyMed plans to raise $55 million on NASDAQ.

Israel’s Pluristem Therapeutics has announced that the improvement in muscle force of hip-replacement patients treated with its PLX-PAD cells was 40-times better than those who received a placebo.

(Thanks to Israel21c) Israel’s TouchéMedical is developing the world’s smallest, cheapest and smartest patch pump, for patients of all ages with diabetes, Parkinson’s and other chronic conditions.

Israel’s MediSafe is opening an office in Boston.  It will help market MediSafe’s medication reminder app, which up to now has been promoted mainly by world of mouth.  Despite this, the app has been downloaded 1.3 million times and is used regularly by hundreds of thousands.   

Representatives from 60 countries will attend Israel’s MEDinISRAEL conference from 23-26 March.  They will join 120 Israeli medical device companies and biotechs to discuss and demonstrate Israel’s latest developments in medical innovation.

Aziz Kaddan and Anas Abu Mukh began degree courses at Haifa University when they were 16 years old.  They were just 19 when they thought up Myndlift - an app that teaches ADHD children and adults to concentrate by using their brainwaves to display a bright image.

A team of Israeli and Japanese researchers has embarked on a project to discover how autistic spectrum disorder develops in the brain. It follows the conference “Advances in Brain Sciences”, jointly hosted by the Weizmann Institute of Science and Japan’s RIKEN Brain Science Institute.

Hebrew University of Jerusalem researchers have discovered that neutrophils (a form of white blood cell) contain many different subtypes. Some of these prevent cancer and others promote it. It opens avenues for therapies that increase anti-tumor neutrophils and limit pro-tumor ones.